Cytosorbents Corp
For the period ended Dec 31, 2023. Filed Mar 15, 2024.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2023 · Filed Mar 15, 2024
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Item 16. Form 10-K Summary
None.
SIGNATURES
In accordance with Section 13 or 15(d) of the Exchange Act, CytoSorbents Corporation has caused this report to be signed on its behalf by the undersigned, thereunto duly authorized, on this 14 th day of March, 2024.
| CYTOSORBENTS CORPORATION | |
| By: | /s/ Dr. Phillip P. Chan |
| Dr. Phillip P. Chan | |
| Chief Executive Officer |
Pursuant to the requirements of the Securities Exchange Act of 1934, this report has been signed below by the following persons on behalf of the registrant and in the capacities and on the dates indicated.
| Signature | Title | Date |
|---|---|---|
| /s/ Dr. Phillip P. Chan | Chief Executive Officer (Principal | March 14, 2024 |
| Dr. Phillip P. Chan | Executive Officer) and Director | |
| | ||
| /s/ Kathleen P. Bloch | Chief Financial Officer | March 14, 2024 |
| Kathleen P. Bloch | (Principal Financial and Accounting Officer) | |
| | ||
| /s/ Michael G. Bator | Chairman of the Board | March 14, 2024 |
| Michael G. Bator | | |
| | ||
| /s/ Alan D. Sobel | Director | March 14, 2024 |
| Alan D. Sobel | | |
| | ||
| /s/ Edward R. Jones | Director | March 14, 2024 |
| Edward R. Jones | | |
| | ||
| /s/Jiny Kim | Director | March 14, 2024 |
| Jiny Kim | ||
FINANCIAL STATEMENTS
| Page | |
| Management’s Report on Internal Control Over Financial Reporting | F-2 |
|---|---|
| Report of Independent Registered Public Accounting Firm | F-3 |
| Consolidated Balance Sheets at December 31, 2023 and 2022 | F-5 |
| Consolidated Statements of Operations and Comprehensive Loss for the years ended December 31, 2023, 2022 and 2021 | F-6 |
| Consolidated Statements of Changes in Stockholders’ Equity for the years ended December 31, 2023, 2022 and 2021 | F-7 |
| Consolidated Statements of Cash Flows for the years ended December 31, 2023, 2022 and 2021 | F-8 |
| Notes to Consolidated Financial Statements | F-9 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.